Navigation Links
Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2011 Results
Date:2/27/2012

, our ability to commercialize KRYSTEXXA; our ability to retain the personnel whom we have hired and to hire the remaining personnel necessary to complete the build out of our commercial team; our reliance on third parties to manufacture KRYSTEXXA; the risk that the market for KRYSTEXXA is smaller than we have anticipated; competition from existing therapies and therapies that are currently under development, including therapies that are significantly less expensive than KRYSTEXXA; our ability to gain market acceptance for KRYSTEXXA among physicians, patients, health care payors and others in the medical community; whether we are able to obtain financing, if needed; economic, political and other risks associated with foreign operations; risks of maintaining protection for our intellectual property; risks of an adverse determination in intellectual property litigation; and risks associated with stringent government regulation of the biopharmaceutical industry and other important factors set forth more fully in our reports filed with the Securities and Exchange Commission, to which investors are referred for further information. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements, which speak only as of the date of publication of this press release. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that we may make. We do not have a policy of updating or revising forward-looking statements and, except as required by law, assume no obligation to update any forward-looking statements.

SVNT-ISAVIENT PHARMACEUTICALS, INC.CONSOLIDATED BALANCE SHEETS(In thousands, except share data)December&#
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Savient Pharmaceuticals to Present at the Cowen and Company 32nd Annual Health Care Conference
2. Savient Pharmaceuticals to Present at the Citi 2012 Global Health Care Conference
3. Savient Pharmaceuticals Appoints David Y. Norton Interim Chief Executive Officer
4. Savient Pharmaceuticals Appoints Experienced Pharmaceutical Executive, David Veitch as President of Savient Europe
5. Savient Pharmaceuticals Announces Permanent J-Code Assigned for KRYSTEXXA®
6. Savient Pharmaceuticals to Present at the Noble Financial Capital Markets Eighth Annual Equity Conference
7. Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting
8. Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results
9. Savient Pharmaceuticals to Hold Third Quarter 2011 Financial Results Conference Call on Thursday, November 3, 2011
10. Savient Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
11. Savient Pharmaceuticals Names Kenneth J. Zuerblis Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... VIEW, California , 20 de octubre de ... líder en el campo de la pulmonología intervencional, ... su Estudio RENEW, casi 3 meses antes de ... fundamental de exención de dispositivo de investigación (IDE) ... Medicamentos) para el sistema de espiral de reducción ...
(Date:10/20/2014)... Oct. 20, 2014 Valeritas, Inc., a leader ... patients with Type 2 diabetes, announced today that it ... Award. The award was presented October 16 th ... Columbus, Ohio . The Cardinal ... a variety of metrics specifically targeted at the importance ...
(Date:10/20/2014)... Oct. 20, 2014 Lpath, Inc. (NASDAQ: ... bioactive lipid-targeted therapeutics, received official notification from the European ... another key patent supporting its iSONEP™ and ASONEP™ ... European patent No. 2087002, claims compositions of matter ... two lead compounds, iSONEP and ASONEP. Sonepcizumab is ...
Breaking Medicine Technology:PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 4
... Company (Nasdaq: PRGO;TASE) today announced that Perrigo CFO Judy Brown ... 5, 2011 at 9:30 a.m. (IST) at the TASE Headquarters ... The day will include presentations on the Consumer Healthcare, ... and research and development. Perrigo Company is ...
... PARK, Calif., Oct. 4, 2011 CV Ingenuity, a ... a $16 million Series B round of financing led ... capital firm. Existing investors BioStar Ventures, Synergy Ventures and ... (CVI), which is focused on the development of a ...
Cached Medicine Technology:CV Ingenuity Announces Close of $16 Million Series B Financing Led by NEA 2
(Date:10/20/2014)... JZ Fitness, an independently operated wellness ... programming, authorship, international lecturing and community wellness, created by ... release of the JZ Fitness nutrition app, available on ... thousands of individuals on nutrition, Jenn Zerling (“JZ”) has ... require calorie counting or cumbersome food logging. ...
(Date:10/20/2014)... Ohio (PRWEB) October 20, 2014 Principle ... years, takes pride in manufacturing top-of-the-line absorbent products. ... image of its most popular brand, Tranquility® Premium Protection ... created a new website, gave its packaging a new ... bring the brand message to the public. , The ...
(Date:10/20/2014)... 20, 2014 Myoderm ... Assistant Director of their CentralSource service. ... the innovative turnkey drug sourcing, distribution, and management ... over 12 years of industry experience, in both ... the peak of their international success to help ...
(Date:10/20/2014)... 2014 Succeed is proud to announce that ... participated in the Every Body Walk! campaign by ... project that encourages workers to be more active outside of ... which concluded at the end of September, was a friendly ... metro areas. Participating companies gave their staff pedometers and ...
(Date:10/20/2014)... National Teen Driver Safety Week is October 19-25, ... Pediatrics (Ohio AAP, http://www.ohioaap.org ) is joining the National ... drivers to talk to their teens and always set the ... are the leading cause of death for U.S. teens. In ... and 859 (42%) of those teen drivers were killed in ...
Breaking Medicine News(10 mins):Health News:JZ Fitness Nutrition App Launches on iTunes 2Health News:JZ Fitness Nutrition App Launches on iTunes 3Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2
... Trujillo, demanding urgent action to give priority to the installation ... ,Chair of the AMA’s Rural Reference Group (RRG), Dr ... series of complaints from rural doctors about poor and slow ... medical care for country Australians. ,Dr Rivett, a ...
... growth by certain chemicals in grape juice in both cell ... in other types of tumor have previously been proven by ... October 18 issue of Clinical Cancer Research. In this study, ... the animals. The molecular mechanism of the inhibition of cancer ...
... government researchers say the a new vaccine effective against the ... been developed//. This is likely to lead to formulation of ... may the jump into humans and turn ,just as deadly,feel ... off by unhygienic conditions and overcrowding, caused millions of deaths ...
... County leaders voted on Tuesday to beg the federal government ... Medical Center while they undertake// a drastic downsizing to save ... Supervisors has unanimously approved the reform plan for submission to ... planned to ask CMS to extend $200 million in funding ...
... a big challenge for law enforcement officials in Australia, and a ... lock-ups /arrests due to possession of ice have gone up by ... entire hullabaloo, scientists have not been able to ‘break the ice’ ... about the link between this drug and violent psychosis. , ...
... the Stanford University School of Medicine conducted a study ... ,According to the telephone-based study, at least ... 1-in-8 Americans. Earlier studies have showed that some type ... the population. ,"Our telephone survey suggests that ...
Cached Medicine News:Health News:Telstra Must Send Lifeline to Rural Doctor Landlines 2Health News:Inhibition of Colorectal tumor growth by Grape seed extract 2Health News:Inhibition of Colorectal tumor growth by Grape seed extract 3Health News:LA County gives Approval for Reform Plan for King-Drew Medical Center 2Health News:Internet – Boon or Bane 2Health News:Internet – Boon or Bane 3
... Nd:YAG laser system with a wavelength of 1,064 ... superficial as well as red and blue vein ... patients with darker skin types (1 to 6) ... general improvement of skin texture. The handpieces special ...
... The UroVysion Bladder Cancer Kit (UroVysion Kit) ... 7, 17, and loss of the 9p21 locus ... specimens from persons with hematuria suspected of having ... intended for use, in conjunction with and not ...
A Powerful New Quantitative Immunoassay for Monitoring Bladder Cancer Patients. Useful in Monitoring Patients for,Disease Progression and Recurrence....
ARION is a long-pulsed alexandrite laser system with a wavelength of 755 nm...
Medicine Products: